NASDAQ:QCLS Mymd Pharmaceuticals (QCLS) Stock Price, News & Analysis $0.31 -0.03 (-8.29%) Closing price 11/18/2026 04:00 PM EasternExtended Trading$0.31 0.00 (-0.10%) As of 11/18/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsSEC Filings About Mymd Pharmaceuticals Stock (NASDAQ:QCLS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Mymd Pharmaceuticals alerts:Sign Up Key Stats Today's Range$0.30▼$0.3350-Day Range$0.31▼$1.7152-Week Range$0.28▼$8.17Volume374,222 shsAverage Volume395,088 shsMarket Capitalization$2.51 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview MyMD Pharmaceuticals is a clinical-stage biopharmaceutical company that has focused on developing treatments for inflammatory and age-related conditions. Its work has centered on drug candidates intended to address diseases for which existing treatment options may be limited. The company’s lead candidate, MYMD-1, is an investigational oral therapy designed to regulate inflammatory processes and the immune system. MyMD has studied its potential application across a range of chronic conditions; it is not an approved medicine. MyMD has also advanced Supera-CBD, a synthetic cannabinoid candidate investigated for potential therapeutic uses. The company’s activities have been focused on drug research and development rather than marketing an established portfolio of commercial medicines.AI Generated. May Contain Errors. Read More Mymd Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks15th Percentile Overall ScoreQCLS MarketRank™: 0.758904109585 of 5 starsMymd Pharmaceuticals scored higher than 15% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingMymd Pharmaceuticals has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageMymd Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about Mymd Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Mymd Pharmaceuticals is -0.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Mymd Pharmaceuticals is -0.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMymd Pharmaceuticals has a P/B Ratio of 0.06. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted11.19% of the float of Mymd Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverMymd Pharmaceuticals has a short interest ratio ("days to cover") of 6.16.Change versus previous monthShort interest in Mymd Pharmaceuticals has recently decreased by 8.93%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMymd Pharmaceuticals does not currently pay a dividend.Dividend GrowthMymd Pharmaceuticals does not have a long track record of dividend growth. News and Social Media3.6 / 5News Sentiment0.69 News SentimentMymd Pharmaceuticals has a news sentiment score of 0.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.45 average news sentiment score of Technology companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Mymd Pharmaceuticals this week, compared to 1 article on an average week.MarketBeat Follows1 people have added Mymd Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Mymd Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders0.86% of the stock of Mymd Pharmaceuticals is held by insiders.Percentage Held by Institutions9.64% of the stock of Mymd Pharmaceuticals is held by institutions.Read more about Mymd Pharmaceuticals' insider trading history. Receive QCLS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mymd Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. QCLS Stock News HeadlinesQ/C Technologies Reports Over $10 Million in Cash and Investments to Fund Development of Its Optical Processing UnitNovember 16 at 9:15 AM | globenewswire.comQ/C Technologies Announces Research Collaboration with Sandia National Laboratories, a $5 Billion U.S. Department of Energy LabOctober 1, 2026 | globenewswire.com432 miles southeast of Washington, DC…Spruce Pine, North Carolina, a town of just over 2,000 people, has supplied a material to every major chip maker for nearly four decades, including AMD, Intel, NVIDIA, Samsung and Taiwan Semiconductor. Washington is set to declare it a national strategic resource and ban its export. Apple, NVIDIA and Amazon have committed over $2 trillion, and Morgan Stanley estimates a $10 trillion economic boom. One small U.S. mining company sits at the center of it. | Wall Street Watchdogs (Ad)Q/C Technologies Announces Research Collaboration with Sandia National Laboratories, a $5 Billion U.S. Department of Energy LabSeptember 30, 2026 | globenewswire.comQ/C Technologies Names Yossef Ehrlichman Chief Technology Officer to Lead Optical Processor DevelopmentSeptember 15, 2026 | globenewswire.comQ/C Technologies Appoints Veteran Silicon Photonics Engineer Yossef Ehrlichman as Founding Manager, Photonic Integrated Circuit (PIC) DevelopmentAugust 4, 2026 | globenewswire.comQ/C Technologies Relocates Headquarters to San Francisco in Proximity to World-Class Engineering Experts for Photonic Computing and Optical AI Inference InitiativeJuly 1, 2026 | globenewswire.comQ/C Technologies Relocates Headquarters to San Francisco in Proximity to World-Class Engineering Experts for Photonic Computing and Optical AI Inference InitiativeJune 30, 2026 | globenewswire.comSee More Headlines QCLS Stock Analysis - Frequently Asked Questions How have QCLS shares performed this year? Mymd Pharmaceuticals' stock was trading at $4.33 on May 15, 2026. Since then, QCLS stock has decreased by 92.9% and is now trading at $0.3063. How were Mymd Pharmaceuticals' earnings last quarter? Mymd Pharmaceuticals, Inc. (NASDAQ:QCLS) released its quarterly earnings results on Monday, November, 16th. The company reported ($0.14) EPS for the quarter. How do I buy shares of Mymd Pharmaceuticals? Shares of QCLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings11/16/2026Today11/18/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (2w+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 For the last 2 weeks, QCLS's financial health has been in the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorTechnology Industry Technology Hardware, Storage & Peripherals Sub-IndustryTechnology Hardware, Storage & Peripherals Current SymbolNASDAQ:QCLS CIK1321834 Webwww.qctechnologies.com Phone(856) 848-8698Fax856-848-0269Employees2Year FoundedN/AProfitability EPS (Trailing Twelve Months)($3.48) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$11.63 million Net MarginsN/A Pretax MarginN/A Return on Equity-75.85% Return on Assets-43.09% Debt Debt-to-Equity RatioN/A Current Ratio3.29 Quick Ratio3.29 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.19 per share Price / Book0.06Miscellaneous Outstanding Shares8,190,000Free Float8,120,000Market Cap$2.51 million OptionableN/A Beta2.21 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:QCLS) was last updated on 11/18/2026 by MarketBeat.com Staff. From Our PartnersYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which sto...Profits Run | SponsoredPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | Sponsored432 miles southeast of Washington, DC…Spruce Pine, North Carolina, a town of just over 2,000 people, has supplied a material to every major chip mak...Wall Street Watchdogs | SponsoredBeyond NVDA: The World’s Next #1 Company?This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvi...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mymd Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mymd Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.